ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

BACKGROUND: The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666815/
https://www.ncbi.nlm.nih.gov/pubmed/34593565
http://dx.doi.org/10.1136/ijgc-2021-002933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666815/
https://www.ncbi.nlm.nih.gov/pubmed/34593565
http://dx.doi.org/10.1136/ijgc-2021-002933

Ejemplares similares